Fed. Circ. Affirms Stay Extension In Evista Dispute

Law360, New York (February 25, 2009, 12:00 AM EST) -- A federal appeals court has upheld an extension to the 30-month stay preventing approval of Teva Pharmaceuticals USA Inc.'s proposed generic for osteoporosis drug Evista until an infringement trial with Eli Lilly & Co. begins in March.

The U.S. Court of Appeals for the Federal Circuit on Tuesday found that the lower court had not abused its discretion in granting Lilly's request to extend the stay after Teva submitted revisions to its proposed generic late in the litigation.

Teva first notified Lilly of its abbreviated new...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.